BeSound is a technology company.
BeSound has raised $7.0M across 1 funding round.
BeSound has raised $7.0M in total across 1 funding round.
BeSound has raised $7.0M in total across 1 funding round.
BeSound's investors include Overwater Ventures, Pioneer Fund, Y Combinator, ZAKA Ventures.
BeSound is a healthcare technology startup revolutionizing breast cancer detection for young women through advanced, AI-powered ultrasound screening.[1][2][4] It offers radiation-free, pain-free scans that deliver results in 24-48 hours for a transparent upfront cost of $350, targeting women under 40 with dense breasts where mammograms often fall short.[1][2][4] BeSound serves proactive consumers seeking accessible early detection, solving delays in traditional screening (which can take days), insurance gaps, and stigma around dense breasts or young women's risks, with plans to scale nationwide, reduce costs to $150, and expand to broader women's health imaging.[1][2][4]
Launched September 30, 2025, with $6.8 million in seed funding from Overwater Ventures, Kindred Ventures, Muse Capital, Lux Capital, and Oura CEO Tom Hale, BeSound starts in Los Angeles via partner locations and mobile Sprinter vans, emphasizing a modern, empowering patient experience.[1][2][3][4][5]
BeSound was founded by Bailey Renger, a 26-year-old former NASA researcher and Harvard quantum computing fellow with a physics background, who pivoted from PhD studies after a personal cancer scare in her early 20s.[1][2][3][4] Dismissed by providers and forced to fight for imaging, Renger experienced firsthand the frustrations of inadequate screening for young women, inspiring her to create faster, more accessible ultrasound tech.[1][3][4]
Co-founder John Stanco, Renger's college collaborator in optical physics, brings AI expertise from aerospace and defense, developing algorithms for signal processing and safety-critical software to power BeSound's scans.[3] The company officially launched September 30, 2025, with its $6.8 million seed round, marking early traction amid rising awareness from 2023 FDA dense breast notification rules.[1][2][5]
BeSound stands out in breast cancer screening through:
BeSound rides the consumer health revolution, akin to Oura and Prenuvo, empowering "savvy consumers" to bypass slow insurance-driven systems amid 2023 FDA mandates notifying 40 million U.S. women of dense breasts—straining infrastructure for ultrasounds.[2] Timing aligns with AI's rise in medical imaging for faster, cheaper diagnostics, addressing late-stage breast cancer in young women via early, proactive screening.[1][4]
Market forces favor BeSound: surging demand for women's health tech post-pandemic, investor enthusiasm (e.g., Oura's CEO backing), and gaps in mammography for dense tissue (affecting half of women).[1][2] It influences the ecosystem by normalizing frequent, accessible imaging, potentially reducing late-stage diagnoses and inspiring AI-ultrasound expansions in other areas.[1][2]
BeSound is poised to disrupt breast screening by scaling AI-ultrasound to all U.S. cities, slashing costs, and destigmatizing early checks for young women—aiming to "end late-stage breast cancer."[1] Trends like AI diagnostics, consumer health adoption, and regulatory pushes for dense breast awareness will accelerate growth, with mobile vans enabling rapid expansion beyond LA.[1][3][4]
Expect evolution into a full women's health platform, leveraging Renger's vision and funding momentum; success hinges on AI accuracy proving out at scale, positioning BeSound as a gateway to preventive care in a proactive health era.[2] This seed-stage innovator echoes the urgency of its origin: turning personal frustration into systemic change for millions.
BeSound has raised $7.0M across 1 funding round. Most recently, it raised $7.0M Seed in September 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2025 | $7.0M Seed | Overwater Ventures, Pioneer Fund, Y Combinator, ZAKA Ventures |